Replies to post #254884 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Anavex previously reported interim data of the PART A intensive PK sub-cohort in the first 6 patients of the U.S. Phase 2 Rett syndrome study in which ANAVEX®2-73 (blarcamesine) demonstrated significant improvements of the two global efficacy endpoints, the Rett Syndrome Behaviour Questionnaire (RSBQ) Total score and the Clinical Global Impression – Improvement (CGI-I). ANAVEX®2-73 (blarcamesine) also significantly improved the RSBQ Hand Behaviours and the RSBQ Breathing Abnormalities. In addition, efficacy signals on both caregiver- and clinician-based measures of severity correlated with levels of glutamate, a key biomarker of disease pathogenesis.

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

PR june 16, 2020

Looks like the exceeding enrollment may be tied w/significant improvements noted earlier. RETT is a small, well organized-informed group. They know a good thing when they see one.

[raja48185]

Anavex “has surpassed by 50% the company’s original enrollment target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study in Rett syndrome.” So, Anavex has more patients in the study in the United States than it originally planned to enroll here in the U.S.?

I am assuming that the caretakers have been spreading the word around (and are happy to do that) in the Rett community about A2-73.